Remove DNA Remove Protein Expression Remove RNA
article thumbnail

Building Korro Bio: A CEO’s Perspective on Innovation and Risk Management

LifeSciVC

Founding Vision: Harnessing RNA Editing for Transformative Medicine Korro Bio’s story began in 2018, co-founded by a remarkable group: Jean-François Formela, M.D. Academic specializing in RNA editing). The ability of modifying RNA enabled us to sidestep many of the potential risks associated with permanent DNA editing.

RNA 67
article thumbnail

The Magic of Fast Feedback Loops

Codon

DNA sequencing and synthesis costs have dropped precipitously, in part, because maintaining Carlson curves became a rallying point for the field. One such opportunity, for example, is in protein expression. For starters, we not only need faster, cheaper options (supply) but also people excited to use them (demand).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Future of Drug Discovery: Tackling the Undruggable with New Biotechnologies

DrugBank

The success of PARP inhibitors in BRCA-mutant ovarian and breast cancers validates this approach, and similar strategies are being tested for other DNA repair enzymes. Indirectly Targeting "Undruggable" Proteins Small molecules can also target "undruggable" proteins indirectly by modulating the production of these proteins.

article thumbnail

The Role of Oncology Biomarkers in Personalizing Hematology Treatment Plans

Conversations in Drug Development Trends

Molecular Biomarkers : Encompass various molecules, such as RNA and metabolites, to reflect the physiological state of the cells and their disease pathways. The analysis of circulating tumor DNA (ctDNA) in a liquid biopsy can also permit genotyping and help monitor the effectiveness of chemotherapy.

article thumbnail

Proteogenomics reveals markers of chemotherapy resistance and outcome in triple negative breast cancer

Broad Institute

Data from standard DNA and RNA sequencing approaches were integrated with mass spectrometry-based proteomics and phosphoproteomic analyses to derive more complete molecular portraits of treatment-responsive versus treatment-resistant tumors. These data suggest a multi-omics predictor for chemotherapy response is within reach.

DNA 52
article thumbnail

Five Promising Treatment Areas in Early-Phase Drug Development in 2024

Alta Sciences

Several viral vectors are being used currently, in addition to non-viral vectors, such as oligonucleotides, naked DNA, and lipoplexes and polyplexes. Oligonucleotide-Based Techniques Most oligonucleotide therapies act through antisense mechanisms and are directed against various RNA species.

article thumbnail

A therapy candidate for fatal prion diseases turns off disease-causing gene

Broad Institute

By Greta Friar, Whitehead Institute June 27, 2024 Images of a mouse brain show the effect of a technology called CHARM in turning off the expression of a gene in the brain. CRISPRoff uses building blocks from CRISPR gene editing technology, including the guide protein Cas9 that directs the tool to the target gene.

Disease 142